Loading Events

You are invited to join us at the ISPOR European Congress from 30 November until 3 December, 2021.

At ISPOR Europe, we will share examples of how we work with our sponsors to demonstrate value for market access.

VIEW FULL LIST OF PRESENTATIONS

Assessing the VALUE of Orphan Drugs Using Conventional Cost-Effectiveness Analysis: Is It FIT for Purpose?
Elisabeth Fenwick, John Carter, Marc Botteman

Modelling the Disease Not the Technology: Do Multi-Use Disease Models Represent a Win-Win for HTA Agencies, Patients and Model Developers?
Elisabeth Fenwick

Evaluating the Correlation between Monthly Migraine Days and Quality-of-Life: Utility Analyses to Inform a Japanese Cost-Effectiveness Model for Fremanezumab in Migraine
Elleke Peterse, Craig Bennison, Josef Paris, Anuja Chatterjee

POSB276: Network Meta-Analyses of Nivolumab plus Fluoropyrimidine and Platinum Chemotherapy Versus Recommended Treatment Regimens in 1L Gastroesophageal Adenocarcinoma
Manon Grevinga, Walter Bouwmeester, Jelle Spoorendonk

POSB3: Multidimensional Treatment Effect Network Meta-Analysis to Estimate Survival of Therapies for Patients with First-Line (1L) Advanced or Metastatic Renal Cell Carcinoma (ARCC) in France
Anna Gittfried, Mark Lambton, Katharina Nickel, Sonja Kroep

POSA320: Development of A Decision Algorithm for Fractional Polynomial (FP) Model Selection in Network Meta-Analysis (NMA); Why Statistical Fit Criteria Alone Is Not Enough
Svenja Petersohn, Mark Lambton, Sonja Kroep

POSA150: Cost-Effectiveness Analysis of First-Line (1L) Systemic Treatments in Advanced Renal Cell Carcinoma (aRCC) in France
Susan Tempelaar, Sonja Kroep, Nishit Dhanji

POSC107: Long Term Outcomes for Patients with Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: A Modelling Study Exploring the Benefit of Gene Therapy
Claire Simons, Poojee Sudhapalli, Josef Paris, Craig Bennison

POSB96: Economic model for a gene therapy in an utlra-rare-disease: Expert validation of approach and assumptions
Claire Simons, Josef Paris, Craig Bennison

POSB302: Assessing the viability of a surrogace relationship between disease-free survival (DFS) and overall survival (OS) for the patients in clinical trials for adjuvant treatment of muscle-invasive urothelial carcinoma (MIUC) following radical cystectomy
Arme Barkema, Claire Simons, Sonja Kroep

POSB11: Correlation and Prognostic Value of Surrogate Endpoints and Overall Survival (OS) in Multiple Myeloma (MM): A Systematic Literature Review (SLR)
Ibrahim Diakite, Elleke Peterse, Alexa Stewart, Jelle Spoorendonk

POSA35: Lifetime Survival Estimates for Nivolumab+Ipilimumab and Sunitinib in Previously Untreated Patients with Advanced/Metastatic Intermediate- or Poor (I/P)-Risk Renal Cell Carcinoma (1L ARCC) Based on 5-Year Minimum Follow-up DATA from CheckMate 214
Venetia Qendri

POSC8: Burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency in Italian Patients from Symptomatology and Motor Development Perspective
Samira Saberian, Philippa Rowan, Priya Patel

POSC69: Healthcare Resource Consumption Associated with Aromatic L-Amino Acid Decarboxylase Deficiency (AADC-D) in Italy
Samira Saberian, Philippa Rowan, Priya Patel

POSB238: Disease burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: Healthcare resource use (HCRU) overall and by disease severity
Samira Saberian, Philippa Rowan, Priya Patel

POSA192: Disease burden of Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency: signs and symptoms
Samira Saberian, Philippa Rowan, Priya Patel

POSA7: Clinical and Health-Related Quality of Life (HRQoL) Outcomes from Interventional Studies in First-Line (1L) Advanced or Metastatic Urothelial Cancer (mUC): A Systematic Literature Review (SLR)
Nicolai Braun, Prashant Auti, Emanuele Arca, Cathelijne Alleman

POSA58: Cost-effectiveness (CE) Analyses for First-line (1L) Treatment of Advanced or Metastatic Urothelial Carcinoma (mUC): A Systematic Literature Review (SLR)
Nicolai Braun, Prashant Auti, Emanuele Arca, Cathelijne Alleman

POSB53: Healthcare Resource Utilization (HCRU) and Cost Studies in Patients Receiving First-line (1L) Therapy for Advanced or Metastatic Urothelial Carcinoma (mUC): A Systematic Literature Review (SLR) 
Prasant Auti, Nicolai Braun, Emanuele Arca, Cathelijne Alleman

POSB340: Availability of Published Health-related Quality of Life (HRQoL) Data for Patients Receiving First-line (1L) Treatment for Advanced or Metastatic Urothelial Carcinoma (mUC): A Systematic Literature Review (SLR) 
Prasant Auti, Emanuele Arca, Nicolai Braun, Cathelijne Alleman

POSB8: Efficacy and safety results from randomized controlled trials evaluating adjuvant treatment after radical resection of muscle invasive urothelial carcinoma – a systematic literature review 
Aiswarya Shree, Dominika Rekowska, Cathelijne Alleman

POSC6: Efficacy and safety results from real-world studies evaluating adjuvant treatment after radical resection of muscle invasive urothelial carcinoma – a systematic literature review 
Aiswarya Shree, Dominika Rekowska, Cathelijne Alleman

POSC56: Healthcare resource use and cost inputs for patients with muscle invasive urothelial carcinoma treated with radical resection – a systematic literature review   
Cathelijne Alleman

POSA342: Reported utilities and health-related quality of life data for patients with muscle invasive urothelial carcinoma treated with radical resection – a systematic literature review
Cathelijne Alleman

POSC64: Healthcare Costs and Resource Utilization in 1L Maintenance (1L MT) Treatment (Tx) of Advanced Non-Small Cell Lung Cancer (aNSCLC): A Systematic Literature Review  
Dorothea Heldt, Sonya Snedecor, Jelle Spoorendonk, Aiswarya Shree, Dominika Rekowska

 

 

Go to Top